Eli Lilly and Company (NYSE:LLY) received a $86.00 price target from Morgan Stanley in a report released on Friday. The firm currently has a “hold” rating on the stock. Morgan Stanley’s price target points to a potential downside of 1.88% from the stock’s current price.

A number of other equities analysts also recently issued reports on the company. Berenberg Bank reissued a “buy” rating and set a $98.00 target price on shares of Eli Lilly and in a research note on Friday, August 4th. Goldman Sachs Group, Inc. (The) reissued a “buy” rating and set a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research note on Thursday. Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research note on Wednesday, July 26th. BMO Capital Markets reissued an “underperform” rating and set a $73.00 target price on shares of Eli Lilly and in a research note on Wednesday, July 26th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $89.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average price target of $88.42.

Eli Lilly and (NYSE LLY) opened at 87.65 on Friday. The company’s 50-day moving average price is $81.94 and its 200 day moving average price is $82.12. The stock has a market capitalization of $92.47 billion, a PE ratio of 37.93 and a beta of 0.34. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $89.09.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 EPS. On average, analysts forecast that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Eli Lilly and Company (LLY) Given a $86.00 Price Target at Morgan Stanley” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/06/eli-lilly-and-company-lly-given-a-86-00-price-target-at-morgan-stanley.html.

In related news, major shareholder Lilly Endowment Inc sold 180,000 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total value of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares in the company, valued at approximately $10,040,562,072.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Joel Isaacson & Co. LLC grew its holdings in shares of Eli Lilly and by 1.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 3,364 shares of the company’s stock worth $283,000 after acquiring an additional 50 shares during the period. Sumitomo Life Insurance Co. grew its holdings in shares of Eli Lilly and by 4.4% in the 2nd quarter. Sumitomo Life Insurance Co. now owns 32,507 shares of the company’s stock worth $2,675,000 after acquiring an additional 1,370 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Eli Lilly and by 7.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 671,327 shares of the company’s stock worth $55,258,000 after acquiring an additional 48,706 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Eli Lilly and by 93.6% in the 1st quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock worth $250,681,000 after acquiring an additional 1,441,200 shares during the period. Finally, Stephens Inc. AR grew its holdings in shares of Eli Lilly and by 4.5% in the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock worth $3,703,000 after acquiring an additional 1,901 shares during the period. Institutional investors and hedge funds own 75.72% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.